Correction

4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

D. Van Der Heijde, Atulya (Atul) Deodhar, O. FitzGerald

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

Original languageEnglish (US)
Article number000582
JournalRMD Open
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Psoriatic Arthritis
Randomized Controlled Trials
Placebos
Certolizumab Pegol

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

@article{12764dc0f9344e71a10b8a5a4a6712dd,
title = "Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)",
abstract = "van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.",
author = "{Van Der Heijde}, D. and Deodhar, {Atulya (Atul)} and O. FitzGerald",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/rmdopen-2017-000582corr1",
language = "English (US)",
volume = "4",
journal = "RMD Open",
issn = "2056-5933",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Correction

T2 - 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

AU - Van Der Heijde, D.

AU - Deodhar, Atulya (Atul)

AU - FitzGerald, O.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

AB - van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

UR - http://www.scopus.com/inward/record.url?scp=85051199045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051199045&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2017-000582corr1

DO - 10.1136/rmdopen-2017-000582corr1

M3 - Comment/debate

VL - 4

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 1

M1 - 000582

ER -